Published: 17 May 2013 European Commission investigators raided the trading offices of three major oil companies and a price reporting agency this week amid complaints about price-fixing and collusion in the global crude oil, refined products and biofuels markets. |
Published: 17 May 2013 While the risks involved in HIV vaccine development have turned Big Pharma away from pursuing a preventative vaccine, government-funded organizations and smaller biotech firms may provide the answer, a GlobalData analyst has said in a research note as World AIDS Vaccine Day approaches. |
Published: 17 May 2013 The introduction of new hepatitis C (HCV) drugs in the second half of 2013 will result in a significant increase in annual treatment costs and can lead to insurers slashing the number of patients eligible for coverage. |
Published: 17 May 2013 Italian pharmaceutical market value will continue to fall in the foreseeable future, due to government support of generics and a stringent drug pricing policy. |
Published: 15 May 2013 Bucking a global trend of falling revenues, weak penetration of generic drugs and an increasing patient population will ensure steady growth of Japan’s Chronic Myeloid Leukemia (CML) market over the next decade. |
Published: 14 May 2013 With the Affordable Care Act (ACA) now covering a range of preventative services within the women’s health sector, major generics manufacturers are taking key steps to ensure they maximize profits in a newly promising market. |
Published: 13 May 2013 China sits firmly behind the wheel of worldwide gasoline demand, as developed nations continue to struggle financially, states GlobalData’s lead refined products analyst. |
Published: 10 May 2013 The medical technology industry may make huge profits from the global obesity crisis, if regulatory hurdles can be overcome and clinical efficacy can be proven. |
Published: 09 May 2013 Recent improvements in the terms offered for oil and gas exploration and production (E&P) in Myanmar signal a clear resolve to attract foreign investment. |
Published: 09 May 2013 While surgical costs remain the driving force behind the adoption of medical tourism, the quality of medical care in emerging countries will dictate their continued success in this blossoming industry. |